Neal Shore, MD, FACS

Neal Shore, MD, Carolina Urologic Research Center

Conference Coverage

Impact of Suspended Enzalutamide Monotherapy on Metastasis-Free Survival Among Patients With High-Risk Biochemically Recurrent Prostate Cancer

01/26/2024

Neal Shore , MD, FACS;

Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.

Neal Shore, MD, discusses...

01/26/2024

Oncology

Videos

Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study

01/18/2024

Neal Shore , MD, FACS;

Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal Shore, MD, FACS, discusses...

01/18/2024

Journal of Clinical Pathways